Condition
Age Related Macular Degeneration (ARMD)
Total Trials
5
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 3 (2)
Trial Status
Not Yet Recruiting1
Unknown1
Active Not Recruiting1
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07330674Phase 1RecruitingPrimary
A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses
NCT06373731Phase 3Active Not RecruitingPrimary
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
NCT07003165Not Yet Recruiting
Research on a New Intelligent Mobile Screening and Diagnosis Pattern for Ocular Diseases
NCT01499628Not ApplicableCompletedPrimary
EFFECT:Eccentric Fixation From Enhanced Clinical Training
NCT04667039Phase 3UnknownPrimary
Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®
Showing all 5 trials